SATPR News – Dec. 14
The data were collected as part of the HPV Infection in Men Study, led by study coauthor Anna R. Giuliano, Ph.D., from the Moffitt Cancer Center and Research Institute. Coauthors from the School of Public Health include Lu-Yu Hwang, M.D., and Michael D. Swartz, Ph.D. Also posted to Medical Xpress and Newswise.
The Weekly Challenger – Dec. 14
Hinson explained it was a chance meeting with entertainer, motivational speaker and cancer care advocate Paul Anthony at a Moffitt Cancer Center event that was the catalyst for changing the “condition” of the journey while keeping the essence of the message. Anthony is a cancer survivor and serves on Moffitt Cancer Center’s National Board of Advisors.
Tampa Bay Times – Dec. 14
For example, the Hillsborough County Industrial Development Authority in recent years has issued bonds, both original issues and refunding, for Tampa General Hospital, Goodwill Industries-Suncoast Inc., University Community Hospital, YMCA, Moffitt Cancer Center, Academy of the Holy Names, South Florida Baptist Hospital, Berkeley Prep, Bay Care Health System Inc., Carrollwood Day School, St. Joseph’s Hospital, John Knox Village Independent Day School, Life Link Foundation (Tissue Bank) and the Tampa Jewish Federation Inc. And the list goes on.
Press Release Point – Dec. 13
Moffitt Cancer Center will celebrate the near completion of its brand new Child Development Center on its McKinley campus.
Nasdaq – Dec. 13
Separately, Iovance said that it has started patient enrollment has begun in a study combining tumor-infiltrating lymphocyte and nivolumab in advanced non-small cell lung cancer patients in collaboration with researchers at H. Lee Moffitt Cancer Center and Research Institute, Stand Up to Cancer and other partners.
SATPR News – Dec. 14
According to the research article published in Journal of the Moffitt Cancer Center, around 1 million breast cancers are diagnosed globally among them 1.7% of cancer cases are triple-negative cancers.
Globe Newswire – Dec. 13
Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that patient enrollment has begun in a study combining TIL and nivolumab in advanced non-small cell lung cancer (NSCLC) patients in collaboration with researchers at H. Lee Moffitt Cancer Center and Research Institute (Moffitt), Stand Up to Cancer and other partners. Also posted to PipelineReview.com.
Covering Health – Dec. 12
The article described an effort by Aetna and the Moffitt Cancer Center in Tampa to establish an oncology medical home to help control costs, reduce clinical inefficiency and duplication of services, and to make it easier for Aetna’s members with cancer to get better access to care.
Marketwired – Dec. 12
"Cancer Treatment: Tackling the Disease through Five Innovative Strategies" -- The panel, headed by Dr. James Mule, Director of Cell-Based Therapies at Moffitt Cancer Center, will probe into the new world of oncology -- targeting innate immunity, modulation of tumor micro-environment, treatment of solid tumors with CAR-T, cancer vaccines and oncolytic viruses.
Futurism Magazine – Dec. 11
Led by Sattva Neelapu, MD, of the MD Anderson Cancer Center, and Frederick Locke, MD, of the H. Lee Moffitt Cancer Center and Research Institute, the treatment involved genetically modifying a patient’s white blood cells/T-cells to attack cancer cells.
83 Degrees – Dec. 12
Being located in USF Connect since late 2014 has saved the company quite a bit in lab costs. Its proximity to Moffitt Cancer Center has enabled it to tap into a pool of talented scientists and technicians.
Business Wire – Dec. 11
“Approximately half of new ALL cases occur in adults age 20 or older and a majority of adult ALL patients relapse and have poor subsequent outcomes,” said Bijal Shah, MD, ZUMA-3 investigator and medical oncologist, Moffitt Cancer Center, Tampa, Fla. Also published in Digital Journal.
American Pharmacists Association – Dec. 11
"This is an extremely valuable therapy for some patients who have no other options," said Frederick Locke, MD, vice chair of the department of blood and marrow transplant and cellular immunotherapy at Moffitt Cancer Center in Tampa, FL, and a lead investigator on the trial.
Street Insider – Dec. 11
“CMML is an aggressive malignancy with few therapeutic options, particularly for those patients who have been treated with hypomethylating agents,” said Eric Padron, M.D., of the Department of Hematologic Malignancies at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, a clinical investigator on this study. Also published on Markets Insider and Buffalo News.
Deccan Herald – Dec. 11
"This is the first FDA-approved gene therapy to treat adult lymphoma. Axi-cel consists of the patients' own T cells that have been reprogrammed, and then re-infused to detect and destroy lymphoma," said Frederick Locke from Moffitt Cancer Center in the US. Also published at Business Standard.
The ASCO Post – Dec. 10
Dr. Balducci, one of the founders of SIOG and considered by many as the father of geriatric oncology, was awarded the SIOG Lifetime Achievement Award for his contributions to geriatric oncology.
Reuters – Dec. 10
“This is an extremely valuable therapy for some patients who have no other options,” said Dr Frederick Locke, vice chair of the department of blood and marrow transplant and cellular immunotherapy at Moffitt Cancer Center in Tampa, Florida and the trial’s co-lead investigator. Also published to AFLnet.net, Markets Insider.
Science Codex – Dec. 10
The findings, reported in the Dec. 10 online issue of The New England Journal of Medicine, and to be presented Dec. 11 at the annual meeting of the American Society of Hematology (ASH) in Atlanta, resulted from a 22-institution study led by Sattva Neelapu, M.D., professor of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center and Frederick Locke, M.D., vice chair and associate member of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center. Also published at Newswise.
NB Herard – Dec. 10
“This is the first FDA-approved gene therapy to treat adult lymphoma. Yescarta consists of the patients' own T cells that have been reprogrammed, and then reinfused to detect and destroy lymphoma,” said Frederick Locke, M.D., co-first author of the article and vice chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center. Also published at Dotemirates.com and Buffalo News.
EurekAlert – Dec. 10
The study was led by Sattva Neelapu, MD, of the MD Anderson Cancer Center and Frederick Locke, MD, of the H. Lee Moffitt Cancer Center and Research Institute. Also published at Newswise.
Business Wire – Dec. 9
Alan List, M.D., President and CEO of Moffitt Cancer Center, who presented on behalf of the investigators, said, “AMV564 eliminated CD33+MDSCs in a dose-dependent manner and restored critical aspects of immune homeostasis.”
The Pharma Letter – Dec. 9
Gilead also added to the news flow, in that the first patient has been dosed with its newly-approved lymphoma drug Yescarta by the Moffitt Cancer Center.
Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.